Ignite Creation Date:
2024-05-06 @ 10:20 AM
Last Modification Date:
2024-10-26 @ 12:28 PM
Study NCT ID:
NCT03221426
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-07
First Post:
2017-07-17
Brief Title:
Study of Pembrolizumab MK-3475 Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction GEJ Adenocarcinoma MK-3475-585KEYNOTE-585
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-10-09
Start Date Type:
ACTUAL
Primary Completion Date:
2024-02-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-06-27
Completion Date Type:
ESTIMATED
First Submit Date:
2017-07-17
First Submit QC Date:
July 17 2017
Study First Post Date:
2017-07-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-16
Last Update Post Date:
2024-05-07
Last Update Post Date Type:
ACTUAL